Exploring molecular phenotypes of incident breast cancer through population-based proteogenomics

Speakers:  Dr. Anders Mälarstig Director of Target Sciences Pfizer Worldwide Research and Development

Original Broadcast date:  November 23 2021

Proteins play key roles in malignant transformation and represent an important hub for oncogenic signaling. Elevated levels of circulating proteins could potentially be identified years before the onset of cancer and its detection by current diagnostics. This webinar focuses on exploring the power of proteomic discoveries, at the population scale in a breast cancer cohort, and the integration of proteogenomics to generate key biological insights into risk prediction that may lead to translational applications for breast cancer prevention.

The webinar covers the following points:

• The importance of integrating multi-omics at a systemic level to generate key biological insights for cancer prevention, diagnosis, and treatment
• Emerging large-scale cancer proteomics analyses at the population level
• Using high-throughput proteomics to find actionable biomarkers to better understand and treat human cancer

If you have any questions about Olink, please contact us at info@olink.com.